3D bioprinted models and organs-on-chips present innovative solutions to bridge the gap and accelerate advances in human-based in vitro models. These technologies enable the creation of physiologically relevant 3D constructs composed of human cells and tissue-based materials that recapitulate human organ, tissue, and disease structure and function.
Pioneers in 3D bioprinting have demonstrated the potential of adopting 3D disease models to provide improved results in future drug screens. The Shrike lab, for example, designed an in vitro tumor model using a tumor-on-a-chip with a bioprinted blood and lymphatic vessel pair (TOC-BBL) utilizing the Allevi 2 bioprinter. Download this application note to learn more about how bioprinting can be used in drug screens that can more closely mimic in vivo drug kinetics.